Resistance mechanisms include the activation of EGFR and stimulation of the EGFR–STAT3–ABCB1 axis, suggesting that EGFR inhibitors may be effective in addressing acquired lenvatinib resistance in HCC [53]. This evidence concerns the gene EGFR and hepatocellular carcinoma.